'Baseline patient characteristics' presentation slideshows

Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research

409 views • 34 slides

Ken Kozuma , MD Teikyo University Hospital On behalf of the MODEL U-SES Investigators

3-month discontinuation of dual antiplatelet therapy after bioresorbable polymer sirolimus -eluting stent implantation: MODEL U-SES study. Ken Kozuma , MD Teikyo University Hospital On behalf of the MODEL U-SES Investigators. Disclosure Statement of Financial Interest.

327 views • 32 slides

Steven E. Nissen MD

STRADIVARIUS Effect of Rimonabant on Progression of Atherosclerosis in Patients with Abdominal Obesity and Coronary Artery Disease. Steven E. Nissen MD.

363 views • 23 slides

When Using DOPPS Slides

When Using DOPPS Slides. DOPPS Slide Use Guidelines. Introduction (1). Introduction (2). Introduction (3). DOPPS Background. Methods (1). Methods (2). Baseline Patient Characteristics for Overall Sample and Severity of Illness Subgroups. Baseline Comorbid Conditions (1).

304 views • 22 slides

Abstract 7500

Abstract 7500. Randomized, Open Label, Phase III Trial of Figitumumab in Combination with Paclitaxel and Carboplatin versus Paclitaxel and Carboplatin in Patients with Non-Small Cell Lung Cancer (NSCLC).

382 views • 20 slides

TBR-652, a Potent Dual CCR5/CCR2 Antagonist in Phase 2 Development for Treatment of HIV Infection

TBR-652, a Potent Dual CCR5/CCR2 Antagonist in Phase 2 Development for Treatment of HIV Infection . David E. Martin, PharmD * Tobira Therapeutics, Inc. *On behalf of TBR-652-2-201 Study Team Abstract 8023, XVIII International AIDS Conference, Vienna, Austria 20 July 2010.

392 views • 17 slides

Flow of Patients Through the Trial

Flow of Patients Through the Trial. Steven E. Nissen, et al. JAMA 2006;295: Published online. Baseline Patient Characteristics*. Steven E. Nissen, et al. JAMA 2006;295: Published online. Laboratory Results (n = 346)*. Steven E. Nissen, et al. JAMA 2006;295: Published online.

230 views • 8 slides